



## PerkinElmer Launches Pre-eclampsia Kit for Enhanced Management

June 10, 2020

*Addition of sFlt-1 for second and third trimester pre-eclampsia management rounds out portfolio*

WALTHAM, Mass. – June 10, 2020 – [PerkinElmer, Inc.](#), a global leader committed to innovating for a healthier world, announced today the addition of the [DELFI<sup>®</sup>A Xpress sFlt-1](#) kit to its CE-IVD pre-eclampsia product offerings. This kit will enable short term prediction of pre-eclampsia and aid in diagnosis in the second and third trimesters of pregnancy together with the previously launched [DELFI<sup>®</sup>A Xpress PIGF 1-2-3™ assay](#). It is easily adaptable for current screening customers using the DELFI<sup>®</sup>A Xpress instrument.

In the second and third trimesters of pregnancy among symptomatic women, the concentrations of DELFIA Xpress sFlt-1 and DELFIA Xpress PIGF 1-2-3 assays can be used to calculate a ratio to predict the onset of pre-eclampsia and for aid in diagnosis. The addition of sFlt-1 completes PerkinElmer's pre-eclampsia product portfolio as the Company now offers different solutions for managing pre-eclampsia during all trimesters.

"For risk assessment and diagnosis of pre-eclampsia, accurate results enable health care to primarily predict and prevent pre-eclampsia and also to provide improved management for all women," said Petra Furu, GM, Reproductive Health, PerkinElmer. "With the sFlt-1 assay, we offer the ability to better manage and assess this condition throughout all stages of pregnancy, furthering PerkinElmer's mission of encouraging healthier families and improved prenatal care."

The newly launched DELFIA Xpress sFlt-1 is the latest product to the family dedicated to the prediction of pre-eclampsia that includes PIGF kits on various platforms as well as the recently launched [Pre-eclampsia Detection Kit](#), the first urinary true point-of-care kit utilizing Congo Red technology.

PerkinElmer's prenatal screening assays and testing solutions are clinically validated and are ideal for all modern prenatal management strategies. The Company's screening solutions are also used in many international prenatal and maternal health studies, including [ASPRE](#), a ground-breaking study into the role of aspirin in the prevention of pre-eclampsia. To learn more about PerkinElmer's prenatal screening platforms and management solutions, please visit [prenataltesting.perkinelmer.com](http://prenataltesting.perkinelmer.com).

### About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately \$2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at [www.perkinelmer.com](http://www.perkinelmer.com).

###

### Contacts:

Media Relations:

Brian Willinsky

(781) 663-5728

[brian.willinsky@perkinelmer.com](mailto:brian.willinsky@perkinelmer.com)